Two COVID-19 vaccine candidates, one from China and the other from the UK, have proven safe for humans and produced strong immune reactions among patients involved in two separate clinical trials, the Lancet medical journal announced on 20th July. The trial of Ad5-nCOV, the vaccine developed by China, has yielded “much better” results in its Phase II in terms of the safety and ability to trigger immune response. The paper said Phase III trials are needed to confirm whether the vaccine candidate effectively protects against SARS-CoV-2 infection. The vaccine developer is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on 18th July. The first trial, which the World Health Organization (WHO) claims is leading the global vaccine race, is from Oxford University. It's regarded as one of the most advanced for development. On Monday, the university published its results from the first phase of human trials, which involved more than 1,000 adults in UK aged between 18 and 55. Scientists say the vaccine contains a "double protection" against the disease. Not only does it produce antibodies – which are the immune system's natural response –…